文献速递免疫规划传染病防控与疫情报告

以色列2004至2019年实施PCV7/13疫苗两剂基础加一剂加强程序后2岁以下婴儿侵袭性肺炎球菌疾病的动态变化:幼儿间接保护的证据

Dynamics of invasive pneumococcal disease in infants < 2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019.
PubMed 文献 · Euro Surveill · 2023-01-01

以色列2009年7月和2010年11月分别启动PCV7和PCV13项目,采用2+1程序(2、4月龄基础剂,12月龄加强剂)。2004至2019年对<24月龄儿童进行基于人群的前瞻性全国主动监测,共记录2,569例IPD。PCV13血清型IPD在所有年龄组下降>90%,所有IPD下降56-70%;7-12月龄婴儿(加强前)与13-23月龄儿童(加强后)PCV13 IPD分别减少97%和98%,显示2+1程序对未完全接种婴儿的间接保护似乎充分。

要点

  • PCV13血清型IPD在所有年龄组下降>90%,所有IPD下降56-70%。
  • 7-12月龄婴儿(加强前)PCV13 IPD减少97%,13-23月龄儿童(加强后)减少98%。
  • 2+1程序对≤12月龄未完全接种婴儿的间接保护似乎充分。

核心结论

  • 2+1 PCV程序实现了对婴儿(包括≤1剂PCV的<4月龄婴儿)的间接(群体)保护,该程序似乎充分。

研究设计与样本

  • 基于人群的前瞻性全国主动IPD监测研究,2004-2019年在以色列<24月龄儿童中开展。
  • 共记录2,569例IPD发作。
  • 按年龄分层:<4月龄(接受≤1剂)、4-6月龄(第2剂后即刻)、7-12月龄(第2剂后数月)、13-23月龄(第3剂后)。
  • 计算晚期PCV(2004-2008)至PCV13前(2016-2019)的年均发病率比(IRR)。

主要发现

  • PCV13血清型IPD在所有年龄组下降>90%,非PCV13血清型IPD似乎增加。
  • 所有IPD发病率在所有年龄组下降56-70%。
  • 7-12月龄婴儿(加强前)PCV13 IPD减少97%,13-23月龄儿童(加强后)减少98%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundPneumococcal conjugated vaccine (PCV)7 and PCV13 programmes started in Israel from July 2009 and November 2010 respectively, with a 2+1 schedule (one dose at 2 months old, one at 4 months old, and a booster dose at 12 months old). Thereafter, invasive pneumococcal disease (IPD) rates substantially declined in children. Uptake of all three doses in < 2-year-olds since 2012 is > 90%. For still incompletely vaccinated infants (≤ 12 months old), how well the PCV 2+1 programme shields from IPD is not fully resolved.AimTo assess the adequacy of protection conferred by the 2+1 schedule PCV vaccination programme, particularly among incompletely-vaccinated infants.MethodsThis was a population-based, prospective, nationwide active IPD surveillance study in Israel, 2004-2019, in children < 24 months old. We estimated annual incidence rates (IR) of overall IPD, IPD caused by PCV13 serotypes (VT13), and non-PCV13 serotypes (NVT13). Annual IPD IRs were stratified by age: < 4 months (receiving ≤ 1 dose), 4-6 months (immediately post dose 2), 7-12 months (a few months post dose 2), and 13-23 months (post dose 3). Late-PCV (2004-2008) to pre-PCV13 (2016-2019) mean annual IR ratios (IRRs) were calculated.Results2,569 IPD episodes were recorded. VT13 decreased > 90% in all age groups, while NVT13 seemed to increase. All-IPD rates declined in all age groups by 56-70%. The 2+1 schedule impact on 7-12-month-old infants (pre-booster) was similar to that on 13-23-month-old children (post booster), with PCV13 IPD reductions of 97% and 98%, respectively.ConclusionsIndirect (herd) protection of infants, including < 4 month-olds with ≤ 1 PCV dose, was achieved by the 2+1 PCV schedule programme which thus seems adequate.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Ben-Shimol S, van der Beek BA, Mor M, et al. Dynamics of invasive pneumococcal disease in infants < 2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019. Euro Surveill. 2023. PMID: 37347413. doi:10.2807/1560-7917.ES.2023.28.25.2200765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。